youtube_live
Q3 2026 earnings • released • EPS beat +27.23% • Revenue beat +128.58%
See resultschevron_right
EDIT:NASDAQ
Editas Medicine Inc
US$2.14
arrow_downward
-10.08%(-0.24) 1D
US$2.14
0.00% (0.00)
todayPre-market
Closed: ኖቬም 12, 4:00:01 ከሰዓት ጂ ኤም ቲ-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
US$2.33
High
US$2.33
Low
US$2.12
Mkt. cap
330.29 ሚ
Avg. vol.
2.35 ሚ
Volume
882.00
52-wk high
US$3.94
52-wk low
US$1.66
EPS
-US$0.62
Beta
2.09
Shares outstanding
154.34 ሚ
No. of employees
87
Open
US$2.33
High
US$2.33
Low
US$2.12
Mkt. cap
330.29 ሚ
Avg. vol.
2.35 ሚ
Volume
882.00
52-wk high
US$3.94
52-wk low
US$1.66
EPS
-US$0.62
Beta
2.09
Shares outstanding
154.34 ሚ
No. of employees
87
News stories
From web sources and news partners
Zacks
·
ከ19 ሰዓቶች በፊት
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc
CEO-
Employees87
Foundedኖቬም 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteeditasmedicine.com